Patents by Inventor Robert S. Langer, Jr.
Robert S. Langer, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11975069Abstract: Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.Type: GrantFiled: January 7, 2021Date of Patent: May 7, 2024Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, TOKITAE LLCInventors: Ana Jaklenec, William Gates, Philip A. Welkhoff, Boris Nikolic, Lowell L. Wood, Jr., Robert S. Langer, Thanh Duc Nguyen, Stephany Yi Tzeng, James J. Norman, Kevin McHugh
-
Publication number: 20230223111Abstract: Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.Type: ApplicationFiled: February 3, 2023Publication date: July 13, 2023Inventors: Philip Ma, Bruce Wilcox, Francois Collin, Chinmay Belthangady, Mi Yang, Manoj Khadka, Manway Liu, John Blume, Robert S. Langer, JR., Ehdieh Khaledian
-
Publication number: 20230187028Abstract: Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.Type: ApplicationFiled: January 5, 2023Publication date: June 15, 2023Inventors: Philip Ma, Bruce Wilcox, Francois Collin, Chinmay Belthangady, Mi Yang, Manoj Khadka, Manway Liu, John Blume, Robert S. Langer, JR., Ehdieh Khaledian
-
Publication number: 20220328129Abstract: Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.Type: ApplicationFiled: March 30, 2022Publication date: October 13, 2022Inventors: Philip Ma, Bruce Wilcox, Francois Collin, Chinmay Belthangady, Mi Yang, Manoj Khadka, Manway Liu, John Blume, Robert S. Langer, JR., Ehdieh Khaledian
-
Publication number: 20220328134Abstract: Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.Type: ApplicationFiled: March 30, 2022Publication date: October 13, 2022Inventors: Philip Ma, Bruce Wilcox, Francois Collin, Chinmay Belthangady, Mi Yang, Manoj Khadka, Manway Liu, John Blume, Robert S. Langer, Jr., Ehdieh Khaledian
-
Publication number: 20140228715Abstract: A method of delivering a substance includes providing a substance at a location in a gastrointestinal (GI) tract, excluding a buccal membrane, of a biological body; and applying ultrasonic waves, having a frequency between about 20 kHz and about 10 MHz, at the location. The method can include storing the substance in at least one reservoir and exposing a medium within or of the GI tract to the substance. The method can further include delivering a device into the GI tract, the device including at least one ultrasound transducer and circuitry; powering the at least one ultrasound transducer and circuitry from within the device; and driving the at least one ultrasound transducer, using the circuitry, in a manner causing the at least one ultrasound transducer to emit ultrasonic waves to a medium within or of the GI tract.Type: ApplicationFiled: May 14, 2012Publication date: August 14, 2014Applicants: The General Hospital Corporation, Massachusetts Institute of TechnologyInventors: Avraham D. Schroeder, Carlo Giovanni Traverso, Baris E. Polat, Kathryn A. Whitehead, Daniel G. Anderson, Robert S. Langer, Jr., Carl Magnus Schoellhammer, Daniel Blankschtein
-
Patent number: 6699470Abstract: A cell delivery device is prepared comprising a controllable degradable gel phase, meshed within a polymer substrate for use in tissue-engineering. The gel phase comprises a degradable, natural or synthetic polymer, and includes a suspension of living cells. The polymer substrate comprises a biocompatible, degradable polymer, and may be synthetic or natural. Degradation of the gel phase may be controlled by enzyme activity or adjustment of gel phase physical properties. In one embodiment, the gel phase contains an enzyme and/or enzyme inhibitor to control degradation of the gel phase. The device is useful in tissue replacement and repair, and more particularly, in the repair of cartilage tissue.Type: GrantFiled: October 10, 2000Date of Patent: March 2, 2004Assignee: Massachusetts Institute of TechnologyInventors: Guillermo A. Ameer, Robert S. Langer, Jr.
-
Patent number: 6355224Abstract: The use of electroactive materials having regions of high electron density as contrast agents in magnetic resonance imaging is described. The electroactive materials may be electroactive polymers, inorganic clusters, carbon clusters, molecules that inherently exhibit electron donor-acceptor behavior having regions or moieties of high electron density, or any combination of the abovementioned contrast agents. The contrast agents of the invention decrease relaxation times of water when introduced into a subject for magnetic resonance imaging. It is particularly preferred that the contrast agents be introduced in the form of a colloidal suspension.Type: GrantFiled: September 17, 1998Date of Patent: March 12, 2002Assignee: Massachusetts Institute of TechnologyInventors: Venkatram R. Shastri, Robert S. Langer, Jr.
-
Patent number: 6190893Abstract: Compositions, methods and systems are provided for the stimulation of biological activities within bone marrow stromal cells by applying electromagnetic stimulation to an electroactive material, wherein the electromagnetic stimulation is coupled to the electromagnetic material. In general the present invention involves attaching or associating the desired bone marrow stromal cells to or with a surface comprising an electroactive material, and applying electromagnetic radiation directly to the desired area. In preferred embodiments, the stimulation of biological activities within bone marrow stromal cells results from inducing one or more activities including, but not limited to, gene expression, cell growth, cell differentiation, signal transduction, membrane permeability, cell division and cell signalling. In particularly preferred embodiments, the present invention stimulates bone cell regeneration.Type: GrantFiled: September 18, 1998Date of Patent: February 20, 2001Assignee: Massachusetts Institute of TechnologyInventors: Venkatram R. Shastri, Nahid Rahman, Ivan Martin, Robert S. Langer, Jr.
-
Patent number: 5232696Abstract: A method and apparatus for reducing the levels of low density lipoproteins (LDL) in blood is disclosed. The LDL is contacted with an enzyme which modifies it in a manner such that the LDL is rapidly removed endogenously by the patients' own metabolic processes. The enzyme may be introduced into the patient by injection, transdermal transport, nasal insufflation and ingestion. Additionally, the enzyme may be contained in a reactor for both in vivo and extracorporeal use.Type: GrantFiled: September 25, 1987Date of Patent: August 3, 1993Assignee: Massachusetts Institute of TechnologyInventors: Robert S. Lees, Robert S. Langer, Jr., Claudy J. P. Mullon, Hugh D. Conlon
-
Patent number: 5178864Abstract: A therapeutically effective amount of soluble phospholipase A.sub.2 is administered into a subject for lowering the low density lipoproteins ("LDL") in the blood. Phospholipase A.sub.2 modifies the plasma LDL by hydrolyzing the phospholipids present in LDL. As a result, the modified LDL is rapidly removed from the bloodstream by the catabolic processes.Type: GrantFiled: August 14, 1990Date of Patent: January 12, 1993Assignee: MITInventors: Robert S. Lees, Robert S. Langer, Jr., Regine Labeque, Claudy J. P. Mullon
-
Patent number: 5019034Abstract: An electrical process for enhancing and/or controlling transport of molecules across tissue such as human and animal skin is disclosed. The process involves the use of a high voltage, short duration electrical pulses on the tissue surface to produce electroporation. Once this effect has occurred, concentration, pressure or temperature gradients, or iontopheresis can be used to move molecules across the tissue. The process can be repeatedly applied without producing undesirable tissue damage or can be used to purposely cause highly limited tissue damage for the purpose of providing a desired, relatively long term molecular transport pathway. The occurrence of the electroporation effect can be detected by monitoring the tissue for a reversible electrical breakdown, which, along with an enhanced tissue permeability, is the characteristic effect of electroporation.Type: GrantFiled: March 30, 1989Date of Patent: May 28, 1991Assignee: Massachusetts Institute of TechnologyInventors: James C. Weaver, Kevin T. Powell, Robert S. Langer, Jr.
-
Patent number: 5019372Abstract: A magnetically responsive composition for the modulated, sustained administration of a biologically active substance, the composition being in the form of a body sized and shaped for placement in the environment of use, the environment including an aqueous fluid, the body comprising, in admixture, a first phase comprising a biocompatible, plastically deformable, polymeric matrix, the polymeric matrix being insoluble in the environment of use, a second phase having a biologically active substance distributed throughout the matrix to be released to the aqueous fluid outside the matrix, and a third phase comprising a magnetically responsive substance encapsulated within the matrix so that, upon exposure of the body to an oscillating magnetic field, the rate of release of the biologically active substance to the aqueous fluid is increased.Type: GrantFiled: September 7, 1990Date of Patent: May 28, 1991Assignee: The Children's Medical Center CorporationInventors: Judah Folkman, Robert S. Langer, Jr., Dean S. T. Hsieh
-
Patent number: 4443545Abstract: Heparinase is produced by growing the bacterium, Flavobacterium heparinum in an improved defined medium consisting of a carbon source, two or more amino acids and several salts in the absence of protein. The carbon source concentration is specifically kept below a certain level to promote improved heparinase production. The sulfate source concentration is also specifically kept below a certain level to promote improved heparinase synthesis. Heparinase can be produced in this medium with or without the addition of an inducer compound.Type: GrantFiled: January 8, 1982Date of Patent: April 17, 1984Assignee: Massachusetts Institute of TechnologyInventors: Robert S. Langer, Jr., Robert Linhardt, Charles L. Cooney, Parrish M. Galliher
-
Patent number: 4391797Abstract: Delivery systems manufactured in the form of polymeric compositions for the controlled delivery of macromolecules to environments of use are disclosed. The systems are characterized as two-phase compositions comprising a phase formed of an insoluble polymeric matrix having limited water sorptivity containing in admixture therein an interpenetrating phase formed of a particulate hydrophilic water swellable, biologically active macromolecular material.Type: GrantFiled: August 10, 1981Date of Patent: July 5, 1983Assignee: The Children's Hospital Medical CenterInventors: Moses J. Folkman, Robert S. Langer, Jr.
-
Patent number: 4357312Abstract: In a method of making a biologically compatible, water-insoluble polymeric body for the controlled, prolonged release of a biologically active substance to a surrounding aqueous environment, the method including forming a liquid mixture containing the polymer, the active substance, and an organic solvent capable of dissolving the polymer, and solidifying the liquid mixture to form the polymeric body, the improvement wherein the liquid mixture further comprises water, the solidification is carried out by cooling the liquid mixture to a temperature sufficiently low to cause the water in the mixture to freeze, thereby creating channels in the body for the release of the active substance therefrom, and removing the organic solvent and the water from the body.Type: GrantFiled: July 16, 1981Date of Patent: November 2, 1982Assignee: The Children's Hospital Medical CenterInventors: Dean S. T. Hsieh, Robert S. Langer, Jr.
-
Patent number: 4341869Abstract: Heparinase is produced by growing the bacteria, Flavobacterium heparinum, in a defined medium consisting of a carbon source, two or more amino acids and mineral salts in the absence of protein. Heparinase is recovered by batch chromatography of the cell extract from hydroxylapatite by elution with sodium chloride and sodium phosphate buffer washes.Type: GrantFiled: August 25, 1980Date of Patent: July 27, 1982Assignee: Massachusetts Institute of TechnologyInventors: Robert S. Langer, Jr., Robert Linhardt, Charles L. Cooney, Parrish M. Galliher
-
Patent number: 4164560Abstract: Delivery systems manufactured in the form of polymeric compositions for the controlled delivery of macromolecules to environments of use are disclosed. The systems are characterized as two-phase compositions comprising a phase formed of an insoluble polymeric matrix having limited water sorptivity containing in admixture therein an interpenetrating phase formed of a particulate hydrophilic water swellable, biologically active macromolecular material.Type: GrantFiled: January 5, 1977Date of Patent: August 14, 1979Inventors: Moses J. Folkman, Robert S. Langer, Jr.